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SUMMARY
Aging of the hematopoietic stem cell (HSC) com-
partment is characterized by lineage bias and
reduced stem cell function, the molecular basis of
which is largely unknown. Using single-cell transcrip-
tomics, we identified a distinct subpopulation of
old HSCs carrying a p53 signature indicative of
stem cell decline alongside pro-proliferative JAK/
STAT signaling. To investigate the relationship be-
tween JAK/STAT and p53 signaling, we challenged
HSCs with a constitutively active form of JAK2
(V617F) and observed an expansion of the p53-posi-
tive subpopulation in old mice. Our results reveal
cellular heterogeneity in the onset of HSC aging
and implicate a role for JAK2V617F-driven prolif-
eration in the p53-mediated functional decline of
old HSCs.
INTRODUCTION
Organismal aging is accompanied by a gradual decline in
regenerative capacities. This decline has been associated
with reduced stem cell function, where the aging stem cell
pool is unable to repopulate tissues upon cellular loss during
physiological turnover or after tissue injury (Beerman et al.,
2010). In the hematopoietic system, stem cell aging is evident
in a weakening of the adaptive immune response and a general
decline of hematopoietic stem cell fitness (Beerman et al.,
2010).
The weakening immune response has been attributed to a
shift from a balanced lymphoid/myeloid output toward amyeloid
skew with age (Rossi et al., 2005). Although hematopoietic stem
cells (HSCs) showing a skew in their myeloid/lymphoid output
can also be found in young mice, the aggregate output is
balanced. In contrast, with age, proportionally fewer lymphoid
biased HSCs are found (Grover et al., 2016).
In addition to the lineage skew, aging of the hematopoietic
system also results in reduced performance in blood reconsti-
tution and engraftment, regardless of lineage output (Dykstra
et al., 2011). In addition, accumulation of DNA damage and up-
regulation of p53 in aged HSC populations is well documented
(Dumble et al., 2007; Rossi et al., 2007). p53 is a key regulator
of aging in hematopoiesis, with high levels of p53 leading to
premature aging features, such as reduced engraftment
(Dumble et al., 2007). However, while Grover and colleagues
(Grover et al., 2016) were able to shed light on the molecular
signature responsible for lineage skewing with age, little is
known about the molecular basis of the functional decline of
HSCs with age. It is, for example, unknown how uniformly the
functional impairment is distributed within the HSC compart-
ment, and it is unclear what factors and pathways are directly
relevant to the decline.
Using an index-sorting strategy and single-cell assays for
highly purified long-term HSCs (LT-HSCs), we identified
HSC aging as a heterogeneous process by characterizing
an HSC subpopulation marked through p53 activation in
old mice. Further transcriptional description of the sub-
cluster shows myeloid bias as well as JAK/STAT- and
MAPK (mitogen-activated protein kinase)-driven pro-prolifera-
tive gene signatures, reminiscent of the proliferation-driven
cell-cycle arrest in cellular senescence (Serrano et al., 1997).
Moreover, expansion of this old-specific subpopulation could
be triggered by constitutively activating Jak2. We propose a
model whereby prolonged proliferation in HSCs driven by
the JAK/STAT pathway leads to a functionally impaired
HSC subpopulation defined by p53 pathway upregulation
with age.
Cell Reports 19, 1503–1511, May 23, 2017 ª 2017 The Author(s). 1503
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
RESULTS
The Long-Term HSC Compartment Harbors a Distinct
Subpopulation with Age
To determine how the transcriptional heterogeneity in long-term
HSCs is associated with age, we index-sorted single LT-HSCs
using ESLAM markers (Figure 1A) from the bone marrow of mice
aged 4 months old (n = 192) and 18 months old (n = 192).
This approach resulted in a distinct HSC population evident
through comparison with two published hematopoietic single-
cell transcriptomedatasets of young andoldHSCs (lineage-nega-
tive Sca-1+, c-Kit+, CD150+, and CD48) (Grover et al., 2016;
Kowalczyk et al., 2015), when projecting all datasets onto an
HSC expression atlas (Nestorowa et al., 2016) (Figure S1A). We
obtained 119/192 old and 99/192 young cells after quality control
(Figure S1B; Supplemental Experimental Procedures) and used a
k-means-based consensus clustering approach for single-cell
transcriptomes (SC3) (Kiselev et al., 2017).
One cluster was entirely made up of old HSCs from replicate
mice (referred to as an ‘‘old-specific’’ cluster) (Figure 1B) being
well definedasmeasured by silhouette index ([Si] 0.92; Figure 1D)
and distinct. Marker genes driving cluster formation were calcu-
lated using SC3 (n = 62; Figure 1C; Table S1). To investigate
whether a similar cluster exists in young LT-HSCs, cells were
clustered separately (Figure S1C), with no similar cluster detect-
able (Figure S1C). Re-clustering old LT-HSCs separately identi-
fied the old-specific cluster with an identical subset of marker
genes (Figure S1C). To ensure that differences in cell type
were not driving the clustering, we compared ESLAM markers
from the index sort data with no difference in intensity of
CD45 (p = 0.8925), CD48 (p = 0.4851), CD150 (p = 0.7208), or
EPCR (p = 0.6472) expression (Figure 1E). To validate
the marker genes, we used single-cell differential expression
(SCDE) (Kharchenko et al., 2014) to identify differentially ex-
pressed genes between the old-specific subpopulation and the
other HSCs. SCDE confirmed a subpopulation of old LT-HSCs
expressing marker genes identified by SC3 (Figure 1F). In sum-
mary, we identified a transcriptionally distinct subpopulation of
old LT-HSCs.
The Old-Specific Cluster Is Characterized by Anti- and
Pro-proliferative Pathways
To characterize the old-specific cluster, we characterized the
marker genes underlying the clustering (Figure 1C; Table S1).
One of the top marker genes, the cell-cycle regulator Cdkn1a, is
a well-known p53 target (Beckerman and Prives, 2010), with p53
previously having been implicated in regulating HSC aging and
quiescence (Dumble et al., 2007). To further test p53 regulation
of the old-specific cluster, we used a list of senescence-specific
p53 genes (Kirschner et al., 2015). We identified a significant
enrichment of marker genes as p53 related (6/68 marker genes,
p = 1e06; Figure 2A; Table S1), many of which are negative reg-
ulators of proliferation. We were unable to identify enrichment of
p53 apoptosis (p = 0.5; Kirschner et al., 2015), autophagy
(p = 0.06; Kenzelmann Broz et al., 2013), or checkpoint (p = 0.12;
Kenzelmann Broz et al., 2013) targets in the marker genes (Fig-
ure 2A; Table S1). No p53 targets were detected in the marker
genes of the other five clusters in Figure 1C (see Table S1).
In the marker gene list, we noted multiple jun/fos transcription
factors that are targets of JAK/STAT signaling in the hematopoi-
etic system, where JAK/STAT stimulates proliferation and differ-
entiation (Rawlings et al., 2004). To test for enrichment of JAK/
STAT targets, we compared the marker genes with chromatin
immunoprecipitation sequencing (ChIP-seq) data from patient
megakaryocytes, where the JAK/STAT pathway drives disease
(Lau et al., 2015). We identified a significant enrichment of
STAT targets (Lau et al., 2015) in our marker genes (green fields
in Figure 2A: p = 0.0005 for pStat3 targets 6/68, and p = 0.0006
for pStat5 targets 4/68; Table S1). No Stat3 or Stat5 targets were
detected in the other five clusters in Figure 1C (Table S1). In
summary, analysis of the marker genes suggested a co-activa-
tion of cell-cycle repressing p53 and pro-proliferative JAK/
STAT signaling in the old-specific cluster.
Several lines of evidence are consistent with the concept that
pro-proliferative and anti- proliferative stimuli exist in the same
old HSC subpopulation. First, unbiased KEGG (Kyoto Encyclo-
pedia of Genes and Genomes) pathway analysis of the marker
genes (Kanehisa et al., 2012) revealed an enrichment for ‘‘cell
cycle’’ due to the presence of cell-cycle inhibitors, p53 targets
(Figure 2B, red bars), and the MAPK pathway (Figure 2B, green
bar), which is driven by JAK activation in hematological cells
(Vainchenker and Constantinescu, 2013).
Second, we compared gene target lists for p53, STAT3, and
STAT5 to marker genes for the old-specific HSC cluster. Gene
set enrichment analysis (GSEA) (Subramanian et al., 2005) high-
lighted a significant enrichment of senescence-specific p53 (p53
enrichment score [ES] = 0.11, p = 0.009), STAT3 (ES = 0.137,
p < 0.001), and STAT5 (ES = 0.084, p = 0.039) targets in those
marker genes (Figure 2C). No enrichment of apoptosis (no values
returned; data not shown) or checkpoint-related p53 targets
(p = 0.44; Figure S2A) were detected. GSEA found no enrichment
of p53 and STAT3/5 targets comparing pooled young and old
HSCs (p = 0.422 for p53 apoptosis, p = 0.65 for p53 RIS,
p = 0.44 for Stat5, and p = 0.357 for Stat3; Figure S2B; data
not shown).
Third, we generated a JAK/STAT signature mimicking HSC
behavior by stimulating a stem-cell-like cell line (HPC7) with
thrombopoietin (TPO) for microarray analysis (Figure 2D) (Park
et al., 2016). Binding of TPO to its receptor activates JAK2 and
its downstream targets STAT1, -3, and -5 (Rawlings et al.,
2004). GSEA highlighted a strong enrichment of TPO-regulated
genes (top 100 genes, p < 9.81e10) in the old-specific cluster
(Figure 2D).
Lastly, we confirmed the old-specific cluster by indirect
immunofluorescence (IF) in HSCs from young and old mice
(n = 3) for p53 phosphorylated at serine 15 (pp53Ser15) and
FosB phosphorylated at serine 27 (pFosBSer27). Only old
HSCs showed high levels of pp53Ser15 and pFosBSer27 (Fig-
ure S2C). p53 response and senescence are associated with
persistent levels of DNA damage. We stained old HSCs for
p53 for gH2AX by IF and blind scored cells with more than
five gH2AX foci. We found an enrichment for gH2AX over p53-
positive cells (Figure 2E; Figure S2D), providing a mechanism
for p53 upregulation. We tested the gH2AX-positive old HSCs
for changes to proliferation by EdU injection into mice and co-
staining for gH2AXpSer139 protein using IF. EdU incorporation
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Figure 1. LT-HSCs Display a Distinct Subpopulation with Age
(A) Sorting strategy for HSCs.
(B) SC3 clustering of young and old HSC transcriptomes. Replicates: purple and green bars. Age: orange (young) and turquoise (old) bars. Similarity between cells
is indicated from blue to red (identical). Rep, replicate.
(C) Heatmap of top ten marker genes of cluster 1. Expression is shown from blue (low) to red (high).
(D) Silhouette plots for all clusters. The silhouette index (si) and the number of cells per cluster are given. xSi, average silhouette index.
(E) Boxplots for ESLAM marker intensity for old-specific (blue) and other old (red) HSCs. Rel. Expr., relative expression.
(F) SCDE plots for marker genes of cluster 1 in young (blue) and old (orange) HSCs. Expression levels of individual cells are indicated by individual lines.
See also Supplemental Experimental Procedures.
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Figure 2. Age-Specific Cluster Carries Signature of Pro-proliferative and Anti-proliferative Stimuli
(A) Manual annotation of top 20marker geneswith Ras senescence (RIS), apoptosis (Kirschner et al., 2015), and pStat3 and pStat5 datasets (Lau et al., 2015). Red
indicates p53, and green indicates pStat targets.
(legend continued on next page)
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was absent from gH2AX-positive cells, suggesting reduced pro-
liferation (Figure 2F).
The Old-Specific Cluster Is Enriched for Myeloid-Biased
HSCs and Regulated by Transcription Factors
Controlling Quiescence and Proliferation
One feature of the aging HSC compartment, the myeloid basis,
has been described on a single-cell basis (Grover et al., 2016).
To identify lineage biases in our old-specific cluster, we overlaid
our marker gene list with gene sets for bi-potent granulocyte/
macrophage progenitors (preGM), megakaryocyte/erythroid
progenitors (preMeg), and common lymphoid progenitors
(CLPs) using GSEA (Pronk et al., 2007). We identified an enrich-
ment of preGM genes (ES = 0.2, p < 0.01), with no enrichment in
preMeg or CLP genes (Figure 2G), suggesting a myeloid bias in
our old-specific HSC cluster. These results could explain the
myeloid bias emerging with age where a subset of myeloid-
primed HSCs reconstitute the blood system more frequently
over time, followed by exhaust, leaving a large pool of myeloid-
primed progenitors in the system.
We interrogated the marker genes specific to our old-specific
HSCs with respect to regulation of HSC function and found 8/12
transcription factors regulating quiescence and proliferation
(Table S2, p = 6.779747e24). Nuclear receptor subfamily 4
group A member 1 (Nr4a1) has been reported to be upregulated
on myeloid-biased HSCs (Land et al., 2015), further supporting
the myeloid bias. Perturbations of some marker genes have
been reported and suggest an enrichment for quiescence regu-
lators in the old-specific subcluster (Table S3).
Constitutive Jak2 Activation Increases Contribution to
the Age-Specific Subpopulation of LT-HSCs
The upregulation of the p53 pathway in Jak2 context has previ-
ously been reported in erythroblasts from patients with myelo-
proliferative disease (MPN) (Chen et al., 2014). In the majority
of MPNs, Jak2 is constitutively active through amutation leading
to JAK2V617F (Baxter et al., 2005), where p53 is thought to
maintain genome stability in the chronic phase of disease
(Chen et al., 2014). In this study, we did not observe activation
of p53 in proliferating young HSCs (Figures 1C and S1C). One
explanation for the lack of p53 activation in young HSCs is that
p53 upregulation correlates with number of replications, similar
to the role of p53 in replicative senescence (Beause´jour et al.,
2003). To test the association between JAK/STAT-driven prolif-
eration and p53 activation, we used single-cell approaches in
homozygous JAK2V617F mice, where JAK2V617F provides
a constant proliferative stimulus (Li et al., 2014). We first charac-
terized proliferation kinetics of single young and old wild-type
(WT) and JAK2V617F HSCs in vitro and found a significant
increase in proliferation in young JAK2V617F HSCs after 72 hr
in culture (p = 0.002, first division; p = 0.0001, second division;
p = 0.0001, third division) (Figures 3A and 3B). Consistent with
our transcriptomic data (Figure 3C), we failed to detect p53 acti-
vation in young JAK2V617F HSCs by IF for pp53Ser15 (Fig-
ure 3D), concluding that JAK2V617F increases proliferation
without evoking a p53 response in young LT-HSCs. We tested
whether JAK2V617F exerts an effect with age through a pro-
longed, lifelong increase in proliferation. We found two lines of
evidence agreeing with prolonged, and not acutely enforced,
proliferation evoking the old-associated p53 signature. First,
we characterized the proliferation kinetics of single old
JAK2V617F HSCs in vitro where old JAK2V617F HSCs show a
loss of JAK2V617F-driven increased proliferation as measured
by numbers of division at 72 hr in culture (p = 0.2117, first divi-
sion; p = 0.0046, second division; p = 0.0039, third division). In
agreement with published data in heterozygous JAK2V617F
context (Kent et al., 2013), old homozygous JAK2V617F HSCs
show a significant decrease in average division when compared
to old WT HSCs at 48 and 72 hr in culture (48 hr: p = 0.007, first
division; p = 0.0001, second division; p = 0.106, third division;
72 hr: p = 0.0338, first division; p = 0.0004, second division;
p = 0.2142, third division) (Figures 3A and 3B). In summary, the
JAK2V617F-enhanced proliferative effect seen in young HSCs
is lost in old HSCs.
Second, to establish causality for Jak2 driving the old-specific
cluster formation, we tested the effect of the long-term increase
in proliferation on individual cells in the aging HSC compartment
using single-cell transcriptomics. We generated single-cell tran-
scriptional profiles of young (n = 70) and old (n = 139) LT-HSCs
homozygous for JAK2V617F (Li et al., 2014). Following clustering
by SC3 (Kiselev et al., 2017), we identified the same old-specific
cluster as in theWT cells, evidenced by an identical set of marker
genes (Figure 3E). A careful comparison of the number of cells in
the old-specific cluster showed that it contained 26% and 33%
of WT cells in replicates 1 and 2 respectively (Figure 3E; data not
shown). In the JAK2V617V homozygous context, this contribu-
tion increased to 32% and 47% for replicates 1 and 2, respec-
tively (Figure 3E; data not shown), a statistically non-significant
increase (p = 0.146). To optimize the number of cells included
in our analysis, we scored 1,463 cells from 3 old and 3 young
WT and JAK2V617F mice (Figure 3D), by positive pp53Ser15
and pFosB IF. In old WT LT-HSCs, we found an increase of
36% in double-positive HSCs when compared to young WT
HSCs, an increase consistent with our scRNA-seq data. The
old-specific cluster expanded to 64% in JAK2V617F HSCs, con-
sisting of significant increase compared to WT (p = 0.0001).
To pinpoint the onset of the p53 signature in LT-HSCs, we
generated single-cell transcriptional profiles of 12-month-old
(B) KEGG pathway analysis of marker genes for old-specific cluster. Selected pathways are shown as ratio of enrichment (green indicates pro-proliferative, and
red indicates anti-proliferative).
(C) GSEA for p53 RIS, apoptosis (Apo), and STAT3 and STAT5 targets. p values and enrichment scores are shown.
(D) Schematic of TPO-regulated microarray experiment in HPC7. GSEA of TPO-specific targets and marker gene list.
(E) IF quantification of old HSCs for p53Ser15 and/or gH2AX (n = 3; error bars indicate SEM).
(F) Quantification of EdU (5-ethynyl-20-deoxyuridine) incorporation, gH2AX, and p53 in old HSCs (n = 3; error bars indicates SEM).
(G) GSEA for lineage markers.
ChIP, chromatin immunoprecipitation, MA, microarray; TGF, transforming growth factor; n.s., not significant; nb, number of genes.
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JAK2V617F mice (n = 2; 130 cells) and WT mice (n = 2; 144 cells)
(Figure 3F). No overlap with the marker genes for the p53 cluster
was found, suggesting that the onset of the p53 signature within
LT-HSCs might be late in the mouse lifespan and a state switch-
like, stochastic event. Taken together, our data suggest that
pro-proliferating constitutive Jak2 activation expands the old-
specific cluster, evoking a p53 response (Figure 3G). We hypoth-
esize that enforced proliferation in youngHSCs leads to stem cell
exhaust and p53 activation with age.
DISCUSSION
The regenerative capacity of a tissue declines with age. Whether
this reduction of stemness is equally distributed between stem
cells or affects only a subset of cells is not well understood. In
this study, only a distinct subpopulation of HSCs carried a signa-
ture indicative of functional decline as characterized by p53
signaling, pointing toward functionally heterogeneous stem cell
aging. Whether this heterogeneous decline in function serves
as a strategy to ensure stem cell function over an entire lifespan
is unclear.
A role for p53 in hematopoietic aging has been established. In
HSCs, increased p53 activity leads to reduced functionality and
proliferation with age, whereas decreased p53 levels increase
HSC proliferative capacity with age (Dumble et al., 2007), sug-
gesting a direct link between p53 dosage and regenerative
capacity in HSCs. Despite the wealth of phenotypical character-
ization of p53 dosage on the HSC compartment as a whole, our
single-cell approach reveals how p53 activation is distributed
within the HSC compartment and provides themissing deconvo-
luted transcriptional signatures of p53-activated and unactivated
aged HSCs. Observations from studies in progeroid and hyper-
activated p53mousemodels suggest amore generalized role for
p53, possibly extending the relevance of our findings to non-
hematopoietic tissues (Varela et al., 2005; Tyner et al., 2002).
We found that p53-activated HSCs co-expressed cell-cycle
inhibitory and proliferative transcripts from MAPK and JAK/
STAT signaling. This co-activation of pro- and anti-proliferative
pathways has been described in senescent cells induced by
hyperactivation of MAPK signaling (Serrano et al., 1997). A role
for JAK2 signaling has previously been implicated in the senes-
cence induction of hematopoietic-lineage-negative Sca+c-Kit+
cells (Li et al., 2010) with accumulation of gH2Ax foci, reduced
rates of proliferation, and inhibition of apoptosis. These phenom-
ena were only observed 26 weeks after JAK2V617F induction,
suggesting a cumulative rather than an immediate effect of
JAK2V617F on proliferation (Li et al., 2010). A link between en-
forced proliferation and stem cell exhaustion has been shown
where loss of CDKN1A drives HSCs into hyperproliferation and
subsequent exhaust (Cheng et al., 2000). A recent study showed
number of cell divisions as a limiting factor in HSC regenerative
capacity (Bernitz et al., 2016). Based on the co-activation of
anti-proliferative pathways of p53 in individual HSCs, the
opposing effects of JAK2V617F on HSC proliferation in young
and old mice and the increase of p53-activated cells under pro-
longed, but not acute, JAK2V617F activation, we provide sup-
port for a link between cumulative proliferation and stem cell
exhaustion with age.
We identified a myeloid bias in the old-specific HSC popula-
tion that could not be detected in the other old HSCs (Figure 2F).
Myeloid bias is well documented in the literature (Rossi et al.,
2005), but molecular mechanisms are, thus far, elusive. We
speculate that myeloid-biased HSCs proliferate more over the
lifetime of a mouse, leading to HSC decline at the same time
as providing a pool of myeloid-biased progenitors reconstituting
the HSC compartment. This heterogeneity in HSC aging might
bemediated by the bonemarrow niche, where it has been shown
that aged HSCs home further away from the endosteum
compared to young HSCs, leading to decreased regenerative
capacity (Geiger et al., 2013). However, this hypothesis awaits
further investigation.
EXPERIMENTAL PROCEDURES
Mice
Mice were generated as described previously (Li et al., 2014). All mice were
kept in specific pathogen-free conditions and all procedures were performed
according to rules of the Animal Welfare and Ethical Review Body (AWERB)
and the UK Home Office regulations.
Cell Isolation and Flow Cytometry
Single cells were obtained from bone marrow suspensions as described pre-
viously (Kent et al., 2013). ESLAM cells were isolated using CD45-FITC (clone
30-F11), EPCR-PE (clone RMEPCR1560), CD150-Pacific Blue (clone TC15),
and CD48-APC (clone HM48-1).
Figure 3. Constitutively Active JAK2 Increases Cell Contribution to the Old-Specific Subpopulation
(A) Kinetics of JAK2V617F andWT HSCs. Ratios of JAK2V617F andWT for indicated divisions in young (black) and old (gray) HSCs. Black line denotes WT levels
(n = 3; error bars indicate SEM). Mut, mutated.
(B) Kinetics data from young (upper row) and old (lower row)WT (blue) and homozygous (Hom) JAK2V671F (red) HSCs. Percentage of all cells upon division (n = 3;
error bars indicate SEM). hrs, hours.
(C) SC3 clustering of HSC transcriptomes from young (yg; upper orange bars) and old (upper turquoise bars) WT (lower orange bars) and JAK2V617F (lower
turquoise bars) mice. Replicates are indicated in green and red. Similarity between cells is indicated from blue to red (identical).
(D) SC3 clustering of old HSC transcriptomes from WT and JAK2V617F mice (replicate 1). Overlap with marker genes is given as a percentage. Cell number for
old-specific HSCs is given as a percentage of all old HSCs.
(E) Immunofluorescent images of old WT and JAK2V617F HSCs stained for pSer15p53 (green), pSer27FosB (red), and DAPI (blue). Bar plots quantify the per-
centage of double-positive HSCs from indicated mice (n = 3; error bars indicate SEM).
(F) SC3 clustering of 1-year-oldWT and JAK2V617F HSCs. Similarity between cells is indicated from blue to red (identical). Overlap with marker genes is shown in
percentages.
(G) Model for relation between proliferation and functional decline of HSCs. Compared are physiological (upper row) against enforced proliferation through
JAK2V617F (lower row). Young HSCs in the JAK2 condition expand faster (number of cells) but exhaust more readily upregulating p53- and cyclin-dependent
kinase inhibitors (CDKNs; shades of red). Arrow cycle indicates self-renewal.
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Single-Cell cDNA and Library Preparation
cDNA from single cells was obtained as described (Picelli et al., 2013). Illumina
Nextera reagents were used for library construction and sequenced on the
HiSeq 2500 Sequencing System (125-bp paired-end [PE] reads).
Data Analysis
Data analysis was performed using SC3 and SCDE tools (Kiselev et al., 2017;
Kharchenko et al., 2014). For details, see the Supplemental Experimental
Procedures.
IF
ESLAM cells were processed as described previously (Li et al., 2010), using
anti-p-Serine15 p53 (clone 16G8), anti-p-Serine139 gH2AX (JBW39), and
anti-p-Serine27 FosB (ab 62433) antibodies. Cells were blinded and scored
on an AxioImager Z2 (Zeiss). A two-sided Fisher’s exact test was used to
calculate p values.
Single ESLAM Cultures
Single ESLAM cells were cultured, blinded, and counted as described previ-
ously (Kent et al., 2013). A two-sided Fisher’s exact test was used to calculate
the p values.
HPC7 Cell Culture and Microarray
HPC7 cells were grown as described previously (Park et al., 2016). For micro-
array, cells were serum starved and stimulated with TPO for 30 min. Total RNA
was extracted using the RNeasy Mini Kit (QIAGEN). Cambridge Genomic
Services processed all samples using Illumina WG-6 BeadArrays. For data
analysis, see Supplemental Experimental Procedures.
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http://dx.doi.org/10.1016/j.celrep.2017.04.074.
AUTHOR CONTRIBUTIONS
K.K., T.C., W.R., and A.R.G. designed the study. K.K., T.C., I.C.M., H.J.P., J.L.,
D.G.K., and R.K. performed experiments. D.F.-S.C., V.K., M.H., and T.C. per-
formed bioinformatics analysis. K.K. analyzed all other data. T.L.H. and D.C.P.
helped with mouse experiments. K.K., T.C., W.R., and A.R.G. wrote the
manuscript.
ACKNOWLEDGMENTS
We would like to thank the CIMR Flow Cytometry Core Facility, especially
Dr. Chiara Cosetti and Dr. Reiner Schulte. The laboratory of Wolf Reik is
supported by the BBSRC (BB/K010867/1), the Wellcome Trust (095645/Z/
11/Z), EU BLUEPRINT, and EpiGeneSys. Work in the A.R.G. lab is supported
by Bloodwise (grant ref. 13003), theWellcome Trust (grant ref. 104710/Z/14/Z),
the Medical Research Council, the Kay Kendall Leukaemia Fund, the Cam-
bridge NIHR Biomedical Research Center, the Cambridge Experimental Can-
cer Medicine Centre, the Leukemia and Lymphoma Society of America (grant
ref. 07037), and a core support grant from the Wellcome Trust and MRC to the
Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute.
K.K. is supported by a Wellcome Trust ISSF Fellowship (grant 105641/Z/14/
Z). The M.H. lab is supported by a Wellcome Trust core grant to the WTSI.
T.C. is supported by a Chancellor’s Fellowship held at the University of Edin-
burgh. W.R. is a consultant and shareholder of Cambridge Epigenetix.
Received: October 15, 2016
Revised: March 21, 2017
Accepted: April 26, 2017
Published: May 23, 2017
REFERENCES
Baxter, E.J., Scott, L.M., Campbell, P.J., East, C., Fourouclas, N., Swanton, S.,
Vassiliou, G.S., Bench, A.J., Boyd, E.M., Curtin, N., et al. (2005). Acquired
mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Lancet 365, 1054–1061.
Beause´jour, C.M., Krtolica, A., Galimi, F., Narita, M., Lowe, S.W., Yaswen, P.,
and Campisi, J. (2003). Reversal of human cellular senescence: roles of the
p53 and p16 pathways. EMBO J. 22, 4212–4222.
Beckerman, R., and Prives, C. (2010). Transcriptional regulation by p53. Cold
Spring Harb. Perspect. Biol. 2, a000935.
Beerman, I., Maloney, W.J., Weissmann, I.L., and Rossi, D.J. (2010). Stem
cells and the aging hematopoietic system. Curr. Opin. Immunol. 22,
500–506.
Bernitz, J.M., Kim, H.S., MacArthur, B., Sieburg, H., and Moore, K. (2016).
Hematopoietic stem cells count and remember self-renewal divisions. Cell
167, 1296–1309.e10.
Chen, E., Ahn, J.S., Massie, C.E., Clynes, D., Godfrey, A.L., Li, J., Park, H.J.,
Nangalia, J., Silber, Y., Mullally, A., et al. (2014). JAK2V617F promotes replica-
tion fork stalling with disease-restricted impairment of the intra-S checkpoint
response. Proc. Natl. Acad. Sci. USA 111, 15190–15195.
Cheng, T., Rodrigues, N., Shen, H., Yang, Y., Dombkowski, D., Sykes, M., and
Scadden, D.T. (2000). Hematopoietic stem cell quiescence maintained by
p21cip1/waf1. Science 287, 1804–1808.
Dumble, M., Moore, L., Chambers, S.M., Geiger, H., Van Zant, G., Goodell,
M.A., and Donehower, L.A. (2007). The impact of altered p53 dosage on he-
matopoietic stem cell dynamics during aging. Blood 109, 1736–1742.
Dykstra, B., Olthof, S., Schreuder, J., Ritsema, M., and de Haan, G. (2011).
Clonal analysis reveals multiple functional defects of aged murine hematopoi-
etic stem cells. J. Exp. Med. 208, 2691–2703.
Geiger, H., de Haan, G., and Florian, M.C. (2013). The ageing haematopoietic
stem cell compartment. Nat. Rev. Immunol. 13, 376–389.
Grover, A., Sanjuan-Pla, A., Thongjuea, S., Carrelha, J., Giustacchini, A., Gam-
bardella, A., Macaulay, I., Mancini, E., Luis, T.C., Mead, A., et al. (2016). Single-
cell RNA sequencing reveals molecular and functional platelet bias of aged
haematopoietic stem cells. Nat. Commun. 7, 11075.
Kanehisa, M., Goto, S., Sato, Y., Furumichi, M., and Tanabe, M. (2012). KEGG
for integration and interpretation of large-scale molecular data sets. Nucleic
Acids Res. 40, D109–D114.
Kent, D.G., Li, J., Tanna, H., Fink, J., Kirschner, K., Pask, D.C., Silber, Y., Ham-
ilton, T.L., Sneade, R., Simons, B.D., and Green, A.R. (2013). Self-renewal of
single mouse hematopoietic stem cells is reduced by JAK2V617F without
compromising progenitor cell expansion. PLoS Biol. 11, e1001576.
Kenzelmann Broz, D., Spano Mello, S., Bieging, K.T., Jiang, D., Dusek, R.L.,
Brady, C.A., Sidow, A., and Attardi, L.D. (2013). Global genomic profiling re-
veals an extensive p53-regulated autophagy program contributing to key
p53 responses. Genes Dev. 27, 1016–1031.
Kharchenko, P.V., Silberstein, L., and Scadden, D.T. (2014). Bayesian
approach to single-cell differential expression analysis. Nat. Methods 11,
740–742.
Kirschner, K., Samarajiwa, S.A., Cairns, J.M.,Menon, S., Pe´rez-Mancera, P.A.,
Tomimatsu, K., Bermejo-Rodriguez, C., Ito, Y., Chandra, T., Narita, M., et al.
(2015). Phenotype specific analyses reveal distinct regulatory mechanism for
chronically activated p53. PLoS Genet. 11, e1005053.
Kiselev, V.Y., Kirschner, K., Schaub, M.T., Andrews, T., Yiu, A., Chandra, T.,
Natarajan, K.N., Reik, W., Barahona, M., Green, A.R., and Hemberg, M.
(2017). SC3: consensus clustering of single-cell RNA-seq data. Nat. Methods
14, 483–486.
1510 Cell Reports 19, 1503–1511, May 23, 2017
Kowalczyk, M.S., Tirosh, I., Heckl, D., Rao, T.N., Dixit, A., Haas, B.J.,
Schneider, R.K., Wagers, A.J., Ebert, B.L., and Regev, A. (2015). Single-cell
RNA-seq reveals changes in cell cycle and differentiation programs upon
aging of hematopoietic stem cells. Genome Res. 25, 1860–1872.
Land, R.H., Rayne, A.K., Vanderbeck, A.N., Barlowe, T.S., Manjunath, S.,
Gross, M., Eiger, S., Klein, P.S., Cunningham, N.R., Huang, J., et al. (2015).
The orphan nuclear receptor NR4A1 specifies a distinct subpopulation of
quiescent myeloid-biased long-term HSCs. Stem Cells 33, 278–288.
Lau,W.W.Y., Hannah, R., Green, A.R., and Go¨ttgens, B. (2015). The JAK-STAT
signaling pathway is differentially activated in CALR-positive compared with
JAK2V617F-positive ET patients. Blood 125, 1679–1681.
Li, J., Spensberger, D., Ahn, J.S., Anand, S., Beer, P.A., Ghevaert, C., Chen, E.,
Forrai, A., Scott, L.M., Ferreira, R., et al. (2010). JAK2 V617F impairs hemato-
poietic stem cell function in a conditional knock-in mouse model of JAK2
V617F-positive essential thrombocythemia. Blood 116, 1528–1538.
Li, J., Kent, D.G., Godfrey, A.L., Manning, H., Nangalia, J., Aziz, A., Chen, E.,
Saeb-Parsy, K., Fink, J., Sneade, R., et al. (2014). JAK2V617F homozygosity
drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient
to sustain disease. Blood 123, 3139–3151.
Nestorowa, S., Hamey, F.K., Pijuan Sala, B., Diamanti, E., Shepherd, M., Lau-
renti, E., Wilson, N.K., Kent, D.G., and Go¨ttgens, B. (2016). A single-cell reso-
lution map of mouse hematopoietic stem and progenitor cell differentiation.
Blood 128, e20–e31.
Park, H.J., Li, J., Hannah, R., Biddie, S., Leal-Cervantes, A.I., Kirschner, K.,
Flores Santa Cruz, D., Sexl, V., Go¨ttgens, B., and Green, A.R. (2016). Cyto-
kine-induced megakaryocytic differentiation is regulated by genome-wide
loss of a uSTAT transcriptional program. EMBO J. 35, 580–594.
Picelli, S., Bjo¨rklund, A˚.K., Faridani, O.R., Sagasser, S., Winberg, G., and
Sandberg, R. (2013). Smart-seq2 for sensitive full-length transcriptome
profiling in single cells. Nat Methods. 10, 1096–1098.
Pronk, C.J.H., Rossi, D.J., Ma˚nsson, R., Attema, J.L., Norddahl, G.L., Chan,
C.K., Sigvardsson, M., Weissman, I.L., and Bryder, D. (2007). Elucidation of
the phenotypic, functional, andmolecular topography of amyeloerythroid pro-
genitor cell hierarchy. Cell Stem Cell 1, 428–442.
Rawlings, J.S., Rosler, K.M., and Harrison, D.A. (2004). The JAK/STAT
signaling pathway. J. Cell Sci. 117, 1281–1283.
Rossi, D.J., Bryder, D., Zahn, J.M., Ahlenius, H., Sonu, R., Wagers, A.J., and
Weissman, I.L. (2005). Cell intrinsic alterations underlie hematopoietic stem
cell aging. Proc. Natl. Acad. Sci. USA 102, 9194–9199.
Rossi, D.J., Bryder, D., Seita, J., Nussenzweig, A., Hoeijmakers, J., andWeiss-
man, I.L. (2007). Deficiencies in DNA damage repair limit the function of hae-
matopoietic stem cells with age. Nature 447, 725–729.
Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997).
Oncogenic ras provokes premature cell senescence associated with accumu-
lation of p53 and p16INK4a. Cell 88, 593–602.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gil-
lette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and
Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based
approach for interpreting genome-wide expression profiles. Proc. Natl.
Acad. Sci. USA 102, 15545–15550.
Tyner, S.D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igel-
mann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002). p53 mutant
mice that display early ageing-associated phenotypes. Nature 415, 45–53.
Vainchenker, W., and Constantinescu, S.N. (2013). JAK/STAT signaling in he-
matological malignancies. Oncogene 32, 2601–2613.
Varela, I., Cadin˜anos, J., Penda´s, A.M., Gutie´rrez-Ferna´ndez, A., Folgueras,
A.R., Sa´nchez, L.M., Zhou, Z., Rodrı´guez, F.J., Stewart, C.L., Vega, J.A.,
et al. (2005). Accelerated ageing in mice deficient in Zmpste24 protease is
linked to p53 signalling activation. Nature 437, 564–568.
Cell Reports 19, 1503–1511, May 23, 2017 1511
